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Neurons Expressing the Highest Levels of -Synuclein Are Unaffected
by Targeted Inactivation of the Gene
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Alun M. Davies,1 and Vladimir L. Buchman1*
Department of Preclinical Veterinary Sciences, University of Edinburgh, Edinburgh EH9 1QH, United Kingdom,1 and
Rinat Neuroscience Corporation, Palo Alto, California 943042
Received 9 June 2003/Returned for modification 18 July 2003/Accepted 14 August 2003
Homologous recombination in ES cells was employed to generate mice with targeted deletion of the first
three exons of the -synuclein gene. Complete inactivation of gene expression in null mutant mice was
confirmed on the mRNA and protein levels. Null mutant mice are viable, are fertile, and do not display evident
phenotypical abnormalities. The effects of -synuclein deficiency on motor and peripheral sensory neurons
were studied by various methods in vivo and in vitro. These two types of neurons were selected because they
both express high levels of -synuclein from the early stages of mouse embryonic development but later in the
development they display different patterns of intracellular compartmentalization of the protein. We found no
difference in the number of neurons between wild-type and null mutant animals in several brain stem motor
nuclei, in lumbar dorsal root ganglia, and in the trigeminal ganglion. The survival of -synuclein-deficient
trigeminal neurons in various culture conditions was not different from that of wild-type neurons. There was
no difference in the numbers of myelinated and nonmyelinated fibers in the saphenous nerves of these animals,
and sensory reflex thresholds were also intact in -synuclein null mutant mice. Nerve injury led to similar
changes in sensory function in wild-type and mutant mice. Taken together, our data suggest that like
-synuclein, -synuclein is dispensable for the development and function of the nervous system.
Several neurodegenerative diseases have been recently coa-
lesced into a distinct group named synucleinopathies (12, 16,
20, 53). Although they are diverse in symptoms and clinical
signs, these diseases share a common histopathological
feature, i.e., formation of large intracellular inclusions whose
principal component is an aggregated small protein,
-synuclein. Neither the normal cellular function of -
synuclein nor the exact mechanism of its involvement in neu-
rodegeneration is clearly understood; possible scenarios are
discussed in many recent reviews (see, for example, references
10, 28, 33, 34, and 43). Even less clear are the normal functions
and roles in neurodegeneration of the other two members of
the synuclein family. Both -synuclein/PNP14 (24, 35) and
-synuclein/BCSG1/persyn (7, 26, 29) have a very high degree
of amino acid similarity with -synuclein within the N-terminal
KTK repeat region of the protein molecule, and this is re-
flected in such common features of synucleins as a native
unfolded state in physiological solutions, reversible binding to
lipid vesicles, and localization in presynaptic terminals (13, 25,
31). However, the C-terminal regions of synucleins, although
all highly acidic, are rather different (7, 29, 52). It is perhaps
this structural diversity that leads to differences in the behavior
of synucleins in vitro and in various in vivo model systems.
Consistent with the finding that -synuclein and -synuclein
are much less fibrillogenic than -synuclein (4, 47, 55), aggre-
gates of these two proteins are not constituents of Lewy bodies
or other histopathological hallmarks of synucleinopathies, al-
though abnormal - and -synuclein-positive structures have
been observed in several cases (15, 17, 49). Recent in vitro
studies have also shown that both - and -synuclein are able
to inhibit fibrillation of -synuclein (40, 55). In transgenic mice
overexpression of -synuclein reduces the severity of neurode-
generative alterations and the number of -synuclein-positive
interneuronal inclusions caused by -synuclein overexpression
(23). Changes of expression of all three synucleins in brain
areas affected in neurodegenerative diseases have been re-
ported (44). Previously we demonstrated that overexpression
of -synuclein, but not -synuclein, kills sensory neurons in
primary cultures (6, 45). Moreover, it has been shown that
-synuclein is able to block JNK signaling, a pathway whose
activation is commonly associated with induction of apoptosis
(39). These observations suggest that the correct balance of
synucleins might be important for survival of at least some
populations of neurons and that decreased expression of
-synuclein might have a proapoptotic effect. The obvious way
to investigate this is to assess whether the absence of
-synuclein affects neurons that normally express these two
proteins. In different vertebrate species, high levels of
-synuclein mRNA are detected from the early stages of em-
bryonic development in two neuronal populations, motoneu-
rons and peripheral sensory neurons (7, 52), and -synuclein is
also expressed in these neurons (18, 32, 52; our unpublished
observations). Moreover, in transgenic mice overexpression of
* Corresponding author. Mailing address: Department of Preclinical
Veterinary Sciences, University of Edinburgh, Summerhall, Edinburgh
EH9 1QH, United Kingdom. Phone: 44-131-6506105. Fax: 44-131-
6506576. E-mail: v.buchman@ed.ac.uk.
† Present address: Department of Biological Chemistry, School of
Medicine, University of Athens, 115 27 Athens, Greece.
‡ Present address: Department of Haematology, Cambridge Insti-
tute for Medical Research, University of Cambridge, Cambridge CB2
2XY, United Kingdom.
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FIG. 1. Targeted inactivation of the mouse -synuclein gene. (a) Scheme for deletion of exons I, II, and III and promoter region of the mouse
-synuclein gene by homologous recombination. The organizations of the wild-type genomic locus (top), targeting vector (middle), and resulting
knockout locus (bottom) are shown. Restriction endonuclease sites: E, EcoRI; B, BamHI; Xb, XbaI; K, KpnI; Bg, BglII. Hybridization probes a
and b, which were used for the analysis of homologous recombination, are also shown. (b) Examples of analysis of homologous recombination in
ES cell lines by Southern hybridization. DNAs from four neomycin-resistant ES cell lines were digested with EcoRI and hybridized with either
probe a or probe b. Only a 20-kb wild-type band is revealed in two clones with random insertion of a PGK-neo cassette, and the homologous
recombination in two other clones results in the appearance of a 17-kb band. Similar results were obtained when DNA was digested with BamHI
and hybridized with probe c. (c) Example of PCR-based genotyping of mice from a litter of two heterozygous parents. (d) Expression of mRNAs
encoding members of the synuclein family in the retinas of wild-type and -synuclein null mutant mice. Results of Northern hybridization with a
full-length mouse -synuclein cDNA probe, a mouse -synuclein-specific probe, a mouse -synuclein-specific probe, and a GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) probe are shown. Note that under the hybridization and washing conditions used, the -synuclein cDNA probe
cross-hybridized with -synuclein transcript (upper panel). High-stringency washes completely eradicated this hybridization signal, with no effect
on hybridization with -synuclein transcript. (e) A Western blot of 10 g of total spinal cord proteins of wild-type and -synuclein null mutant mice
was probed with mouse -synuclein-specific SK23 antibody.
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-synuclein leads to pathological changes in spinal and brain
stem motoneurons (19, 30, 56), suggesting that these neurons
are susceptible to changes in the metabolism of synucleins.
Therefore, we studied populations of motoneurons and pe-
ripheral sensory neurons in -synuclein null mutant mice,
which we produced.
MATERIALS AND METHODS
Generation of -synuclein null mutant mice. To generate a targeting vector, a
1.2-kb XbaI-XbaI fragment from lambda genomic clone PS92 (2) was cloned as
a short arm into an XbaI site of the pPNT vector (54) between PGK-TK and
PGK-neo cassettes. The resulting plasmid was digested with Sse8387I, blunted
with the Klenow fragment of DNA polymerase I, further digested with XhoI, and
used as a vector for ligation with a long arm. DNA of lambda genomic clone PS91
(2) was digested with BglII, blunted with Klenow fragment of DNA polymerase
I, and further digested with SalI, and a 4-kb fragment was used as a long arm in
our targeting vector (Fig. 1a). For electroporation of 129Ola mouse ES cells
(clone E14Tg2a; a gift of A. Smith, Centre for Genome Research, University of
Edinburgh), DNA of the resulting targeting vector was linearized by digestion
with NotI. After electroporation and selection, G418- and ganciclovir-resistant
ES cell clones were checked for correct homologous recombination by Southern
hybridization analysis of EcoRI-digested (for probes a and b in Fig. 1a) or
BamHI-digested (for probe c) DNA. Suitable clones were injected into blasto-
cysts of C57Bl6J mice (Charles River). All procedures involved in generation of
mutant mice were carried out according to the United Kingdom Animals (Sci-
entific Procedures) Act (1986) and other Home Office regulations under specific-
pathogen-free conditions. The presence of a mutant allele in animals was
checked by PCR analysis of DNA extracted from mouse tail biopsies. A common
upstream primer (5-AGTCCTGGCACCTCTAAGCA-3) and primers specific
for the wild-type allele (5-GGGCTGATGTGTGGCTATCT-3) and the PGK-
neo cassette in the mutant allele (5-GAAGAACGAGATCAGCAGCC-3) were
used for amplification. Forty cycles of 45 s at 95°C, 30 s at 56°C, and 60 s at 72°C
were carried out. The presence of 480-bp (for the wild-type allele) and 397-bp
(for the mutant allele) amplification products in the reaction mixture was
checked by electrophoresis in a 1.5% agarose gel. Heterozygous animals were
used for at least six further generations of backcrosses with C57BL6J mice before
null mutant, wild-type, and heterozygous littermates were produced for further
studies by breeding heterozygous males and females. The mutant mouse strain
was registered in the Mouse Genome Information database under the official
name (B6-TgHSNCGtm1VLB).
-synuclein null mutant mice. Generation of -synuclein mutant mice was
described previously (1). We backcrossed these mice with C57Bl6J mice for at
least six generations before setting up intercrosses to produce null mutant,
wild-type, and heterozygous littermates.
Expression studies. Extraction of RNA from mouse tissues, Northern blotting,
and preparation of labeled probes were carried out as described previously (7,
36).
Affinity-purified polyclonal rabbit SK23 antibody generated against a C-ter-
minal peptide of mouse -synuclein (persyn) was used at a 1:500 dilution for
Western blotting and enhanced chemiluminescence detection of this protein in
total cell lysates as described earlier (7, 36). For immunohistochemistry, adult
mouse brains and embryonic day 12 (E12), E15, and E18 embryos were fixed in
4% paraformaldehyde–phosphate-buffered saline (PBS) or Carnoy’s fixative
(60% ethanol, 30% chloroform, 10% glacial acetic acid) at 4°C overnight fol-
lowing dehydration in alcohol series and embedding in paraffin blocks. Eight-
micrometer-thick sections were cut with a Leica or Microm microtome and
mounted on SuperFrost slides (BDH, Poole, United Kingdom) for conventional
staining or on Gold Seal slides (Gold Seal Products, Portsmouth, N.H.) for
immunostaining. The paraffin sections were cleared in xylene and rehydrated
through a graded alcohol series. Endogenous peroxidase activity was quenched
by incubating the slides in 3% H2O in methanol for 20 min. After being washed
with PBS, the tissues were blocked in 10% horse or goat serum and 0.4% Triton
X-100 in PBS for 1 h at room temperature. Incubation with a 1:40 dilution of
SK26 anti-mouse -synuclein antibody was carried out at 4°C overnight. Detec-
tion of immune complexes with biotinylated anti-rabbit antibody and avidin-
peroxidase complex from the Vectastain ABC kit (Vector Laboratories, Peter-
borough, United Kingdom) and diaminobenzidine (Fast 3,3-diaminobenzidine
tablet sets; Sigma, St. Louis, Mo.) as a substrate was carried out according to the
manufacturer’s instructions. Motor nuclei were identified by staining of alternate
sections with hematoxylin-eosin (Raymond A Lamb, London, United Kingdom)
and a goat antibody against choline acetyltransferase (Chemicon, Temecula,
Calif.) at a 1:100 dilution. In the latter case, anti-goat secondary antibody was
used for detection.
Whole-mount immunofluorescence. Mouse triangularis sterni muscle was dis-
sected in PBS and fixed in 4% paraformaldehyde–PBS for 20 min, followed by
incubation with AlexaFluor 647-conjugated -bungarotoxin (5 g/ml in PBS) for
30 min. After washing in PBS and blocking and permeabilization for 1 h in 1%
bovine serum albumin–0.4% lysine–0.5% Triton X-100 in PBS, samples were
incubated overnight with primary antibodies diluted in the same buffer at 4°C.
Mouse monoclonal anti-neurofilament M (clone 2H3; Developmental Studies
Hybridoma Bank, Iowa City, Iowa) and anti-synaptic vesicles (clone SV2; De-
velopmental Studies Hybridoma Bank) antibodies were used at a 1:200 dilution,
and rabbit polyclonal SK23 antibody was used at a 1:40 dilution. After several
washes, incubation with 1:200-diluted secondary antibodies (fluorescein isothio-
cyanate-conjugated goat anti-rabbit immunoglobulins and tetramethyl rhoda-
mine isocyanate-conjugated goat anti-mouse immunoglobulins, both from Jack-
son ImmunoResearch Laboratories, West Grove, Pa.) was carried out for 3 h at
room temperature, followed by extensive washing and mounting in Vectashield
(Vector Laboratories, Burlingame, Calif.). Images were obtained with a Zeiss
LSM 510/Axioplan 2 confocal microscope.
DRG neuron counts. The spinal columns from P2 mice were fixed and em-
bedded as described above. Serial 8-m-thick longitudinal sections were cut,
mounted on SuperFrost slides (BDH), cleared in xylene, rehydrated through a
graded alcohol series, and stained with 0.1% cresyl violet acetate (Sigma). Lum-
bar L6 dorsal root ganglia (DRG) were identified by using characteristic tissue
landmarks on sections. Neurons were identified by virtue of the Nissl substance
and their large, round, pale-stained nuclei (27). Neurons in the L6 DRG dis-
playing a prominent nucleolus were counted on every eighth section. The neu-
ronal number was quantified by using a digital stereology system that employs a
combination of the optical dissector and volume fraction-Cavalieri methods
(Kinetics Imaging, Bromborough, United Kingdom). All counts were carried out
blindly by a person unaware of animal genotypes.
Motoneuron counts. Adult mouse brains were fixed and processed as de-
scribed above for expression studies. The whole brain stem was sectioned into
8-m-thick sections, which were mounted on SuperFrost slides. Rehydrated
sections were stained in a 1% solution of neutral red (Raymond A Lamb) in
distilled water for 30 min, followed by dehydration and mounting as described
above. A stereological fractionator method (22), which allows estimation of the
number of particles independent of the volume of the structure that the particles
are part of and is not affected by tissue shrinkage during processing, was used to
assess the number of motoneurons in five motor nuclei of the brain stem. Large
(20 m in diameter) neurons displaying a prominent nucleolus were counted
in total on every fifth section throughout the nucleus; the first section for count-
ing was randomly chosen from the first five sections that included this nucleus.
Nerve fibers counts. Anesthetized animals were transcardially perfused with
heparinized saline and then 2.5% glutaraldehyde–2% paraformaldehyde–0.1 M
sodium cacodylate buffer (pH 7.3)–1 mM CaCl2 for 5 min. The saphenous nerve
was removed and fixed for 2 h in the same fixative, postfixed in OsO4, and
embedded in araldite. One-micrometer resin sections were prepared and stained
with toluidine blue for light microscopy to measure the area of the nerve cross-
section. Ultrathin 80-nm transverse sections were stained with uranyl acetate and
lead citrate, mounted onto copper slot grids, and examined on a transmission
electron microscope (Phillips BioTwin; FEI, Cambridge, United Kingdom). My-
elinated A-fibers and unmyelinated C-fibers were identified and counted as
described previously (57). The densities of both types of fibers were calculated
after counting of 12 to 15 randomly chosen electron microscope images and
multiplied by the area of the nerve cross-section.
Primary neuronal cultures. Cultures from trigeminal and superior cervical
ganglia were prepared as described previously (42) and maintained in neurobasal
medium with B27 complement (Invitrogen, Carlsbad, Calif.). The number of
neurons attached to each culture dish within a 12- by 12-mm square was counted
3 h after plating and was taken as the initial number of neurons (100%). In
experiments with proteasome inhibitors and metal ions, the initial count was
carried out 24 h after plating. In all cases drugs were added to cultures imme-
diately after the initial count. The number of surviving neurons in the same area
was counted 24 and 48 h later and was expressed as a percentage of the initial
count.
Behavioral tests. All experiments were carried out in accordance with the
United Kingdom Animals (Scientific Procedures) Act (1986). Behavioral testing
was carried out prior to surgery to establish a baseline for comparison to post-
surgical values, as described in detail previously (5, 11). The procedure of chronic
constriction injury (CCI) to the sciatic nerve was modified for mice from a
procedure described previously for rats (3). In brief, adult male mice (90 to
120 g) were anaesthetized with sodium pentobarbital (Sagatal; Rhoˆne Merieux,
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Essex, United Kingdom) (0.06 ml/100 g, intraperitoneally) supplemented with
halothane-O2 (Zeneca, Cheshire, United Kingdom). Under aseptic conditions,
the right sciatic nerve was exposed proximal to the trifurcation, at mid-thigh
level, and three chromic cat gut ligatures were tied to loosely constrict the nerve.
The overlying muscle and skin were closed with sutures, and the animals were
allowed to recover before reflex testing recommenced. Thermal hyperalgesia was
monitored by using noxious radiant heat (30 to 55°C) (Hargreaves’ thermal
device; Linton Instruments, Diss, United Kingdom) applied to the mid-plantar
glabrous surface of the hind paw. The withdrawal response latency was charac-
terized as a brief paw flick, and a standard cutoff latency of 20 s prevented tissue
damage. Mechanical allodynia was measured as the threshold for paw withdrawal
in response to graded mechanical stimuli applied to the mid-plantar glabrous
FIG. 3. -Synuclein in postnatal mouse sensory and motoneurons. -Synuclein is localized in the cytoplasm of cell bodies of mouse P2 DRG
(a) and trigeminal ganglion (b) neurons as well as in nerve fibres in the dorsal root (DR), spinal nerve (SN), and trigeminal nerve (TN). In P2
oculomotor nucleus (c), only -synuclein-negative cell bodies (arrowheads) are seen on the background of neuropil staining, whereas in P2
trigeminal motor nucleus (d), cytoplasmic staining can be detected in some neurons (arrows). Bars, 100 m (a and c) and 20 m (b and d).
FIG. 2. -Synuclein in embryonic mouse sensory and motoneurons. Anti--synuclein staining of E12 (a) and E15 (b) trigeminal motor nuclei and
trigeminal ganglia and of E18 trigeminal motor nucleus (c), E18 oculomotor nucleus (d), E18 trochlear nucleus (e), E18 facial nucleus (f), and E18
hypoglossal nucleus (g) is shown. All nuclei contain labeled neuronal cell bodies, but dotted neuropil stain becoming also obvious in all ganglia at E18.
Arrowheads show -synuclein-positive axons of E12 and E15 motoneurons of the trigeminal motor nucleus (TMN). Sensory neurons of the trigeminal
ganglion (TG) are also intensively stained, as is the root of the trigeminal nerve (rTN). Bars, 100 m (a, c, e, and f), 200 m (b and g), and 50 m (d).
VOL. 23, 2003 -SYNUCLEIN KNOCKOUT 8237
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surface of the hind paw with calibrated von Frey filaments (Stoelting, Wood
Dale, Ill.). The threshold was defined as the pressure (force per unit area) that
caused foot withdrawal five times in every 10 applications, repeated at 1- to 2-s
intervals. The pressure applied to the hind limb by the von Frey filaments is
calibrated as force (millinewtons) divided by the area over which it is applied
(square millimeters).
RESULTS
Generation of -synuclein null mutant mice. Mouse strains
with a targeted deletion of the first three exons of the mouse
-synuclein gene (Fig. 1) were generated from three indepen-
dent ES cell clones as described in Materials and Methods.
Two of these strains were used in this study, and because the
results were identical, the experimental data obtained with
both strains were combined. Mice lacking the -synuclein gene
were viable and fertile and did not show any obvious abnor-
malities in development, behavior, or gross morphology of the
nervous system (data not shown). Western blotting (Fig. 1e)
and immunohistochemistry (not shown) with an antibody spe-
cific to the C-terminal peptide of mouse -synuclein showed a
complete absence of the protein in all tissues of null mutant
mice. Northern hybridization of RNAs from various tissues
confirmed complete inactivation of -synuclein gene function
in null mutant mice, which was not accompanied by compen-
satory increases of - or -synuclein mRNA levels (Fig. 1d and
data not shown).
In the absence of an obvious phenotypic manifestation of the
null mutant genotype in -synuclein knockout mice, we carried
out comparative studies of several neuronal populations with
wild-type and null mutant mice. Motoneurons and peripheral
sensory neurons were chosen because both populations nor-
mally express high levels of -synuclein mRNA (7) but, as
shown below, display different intracellular compartmentaliza-
tion of -synuclein.
Developmental changes of -synuclein compartmentaliza-
tion in motoneurons. Previously we have demonstrated by in
situ hybridization high levels of -synuclein mRNA expression
in spinal and cranial motoneurons from early stages of mouse
and rat embryonic development (7). However, neither the
abundance nor the intracellular localization of -synuclein pro-
tein in these neurons has been studied. Using a specific anti-
body which recognizes the C-terminal peptide of mouse
-synuclein, we now demonstrated that the protein expression
pattern follows the mRNA expression pattern but that dra-
matic changes in compartmentalization of -synuclein within
motoneurons take place during postnatal development. Immu-
nohistochemistry was performed on sagittal as well as coronal
paraffin sections of mouse embryos of different developmental
stages and adult mouse brains. To identify oculomotor, troch-
lear, facial, hypoglossal, and trigeminal motor nuclei, adjacent
sections were stained with hematoxylin-eosin and an antibody
against choline acetyltransferase, a motoneuron marker (see
Materials and Methods). From the early stages (E12) and
throughout the embryonic development, -synuclein is local-
ized in both motoneuron cell bodies and axons (Fig. 2 and data
not shown). However, at E18, in addition to cytoplasmic stain-
ing, a dotted neuropil staining became evident in all studied
motor nuclei (Fig. 2c to g). The pattern is completely different
in motor nuclei of postnatal, particularly adult, mouse brain.
FIG. 5. Average total numbers of motoneurons in brain stem motor nuclei of wild-type (/) and -synuclein null mutant (-/-) adult mice.
Means and standard errors from data obtained from analysis of at least 10 nuclei for each genotype are shown. Statistical analysis (two-tailed,
unpaired Student’s t test) showed no significant difference in cell numbers between the two genotypes for all nuclei (P  0.5).
FIG. 4. -Synuclein in adult mouse motoneurons. (A) -Synuclein in motor axons and nerve terminals at the neuromuscular synapse. Triple
immunofluorescent staining of whole-mount preparations of mouse traingularis sterni muscle is shown. -Synuclein (Ai, green) is colocalized with
neurofilaments in the axon and SV2 in presynaptic terminals (Aiii, red) but not with acetylcholine receptors on postsynaptic membrane (Aii, blue
[stained with AlexaFluor 647-conjugated -bungarotoxin]). Three images are merged in panel Aiv. (B) -Synuclein in oculomotor nuclei
(arrowheads) and the root of oculomotor nerve (rON). A higher magnification shows axonal staining in the nerve root (panel Biv), the absence
of -synuclein in cell bodies of motoneurons, and positive staining of neuronal cell bodies in the median Edinger-Westphal nucleus (E-Wn, panel
Bii). (C) -Synuclein in trochlear nuclei (arrowheads in panel Ci) and the root of trochlear nerve (arrow in panel Ciii and rTN in panel Civ). A
higher magnification shows intense staining of motoneuron axons in the nerve (Civ) and only a dotted neuropil staining in the nucleus (Cii).
(D) -Synuclein in facial nuclei (arrowheads) and the facial nerve. Axonal staining is evident in the internal genu (IgFN) and the root (rFN) of
the nerve (panel Diii). A higher magnification reveals -synuclein in the cytoplasm of a few motoneurons (open arrowhead in panel Dii).
(E) -Synuclein in hypoglossal nuclei (arrowheads in panel Ei and HN in panel Eii) and the root of hypoglossal nerve (rHN in panel Eii). A higher
magnification shows positive staining of the nerve root and neuropil staining in the nucleus (Eii). (F) -Synuclein in the trigeminal motor nucleus
(TMN) and the spinal trigeminal tract (STT). Neuronal cell bodies are not stained; only dotted neuropil staining is evident at the highest
magnification (Fiii).
VOL. 23, 2003 -SYNUCLEIN KNOCKOUT 8239
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At postnatal day 2 (P2), only neuropil staining (Fig. 3c) or very
few neurons with -synuclein-positive cytoplasm on the back-
ground of neuropil staining (Fig. 3d) are evident in these
nuclei. In adult brain all motor nuclei (with the exception of
the facial nucleus, where a few neurons still display positive
cytoplasmic staining) show a complete absence of -synuclein
in the cytoplasm of neuronal cell bodies, but axons in all stud-
ied motor nerve roots display intense -synuclein immunore-
activity (Fig. 4). Using immunofluorescence, we clearly dem-
onstrated that -synuclein is present not only in axons but also
in presynaptic terminals of motoneurons in neuromuscular
junctions (Fig. 4A).
Intracellular localization of -synuclein in mouse sensory
neurons. As in motoneurons, in sensory neurons of embryonic
peripheral ganglia -synuclein is distributed throughout the
cytoplasm of cell bodies and axons (Fig. 2 and data not shown).
However, in contrast to the case for motoneurons, -synuclein
compartmentalization in sensory neurons does not change dur-
ing late embryonic and postnatal development. Postnatal neu-
rons of DRG and cranial sensory ganglia display intensive
immunostaining of their cell bodies as well as nerve fibers with
anti--synuclein antibody (Fig. 3a and b and data not shown).
Numbers of motoneurons in cranial nuclei of wild-type and
-synuclein null mutant mice. Serial coronal sections of adult
mouse brain were prepared and stained, and motoneurons
were counted in five cranial nuclei as described in Materials
and Methods. In neither of these ganglia were statistically
significant differences in the number of neurons between wild-
type and -synuclein null mutant mice found (Fig. 5).
Numbers of sensory neurons in DRG and trigeminal ganglia
of wild-type and null mutant mice. The number of neurons in
L6 lumbar DRG and trigeminal ganglia was assessed in P2
mice, after the period of physiological cell death in these gan-
glia. Serial longitudinal sections of the lumbar part of the
spinal column and transverse sections of the head were stained
and neurons were counted as described in Materials and Meth-
ods. Figure 6a and b show that the absence of -synuclein does
not have an effect on the number of neurons in both sensory
ganglia. Similarly, no effect of the absence of -synuclein on
the neuronal complement in these ganglia was found. Mice
with a targeted inactivation of the -synuclein gene have been
described previously (1), but for this work they were further
backcrossed with C57BL6J mice (as described in Materials and
FIG. 6. Numbers of sensory neurons and nerve fibers in wild-type and null mutant mice. (a and b) Average total number of neurons in
trigeminal ganglia (a) and L6 lumbar DRG (b) of wild-type (/), -synuclein null mutant (	/	), and -synuclein null mutant (	/	) P2 mice.
Means and standard errors of data obtained from analysis of at least 10 ganglia for each genotype are shown. Statistical analysis (Kruskal-Wallis
one-way analysis of variance) showed no significant difference in cell numbers between all three genotypes for both ganglia (P  0.6). (c and d)
Average total numbers of myelinated A-fibers (c) and unmyelinated C-fibers (d) in adult mouse saphenous nerves. Means and standard errors of
data obtained from analysis of at least five nerves for each genotype are shown. Statistical analysis (Kruskal-Wallis one-way analysis of variance)
showed no significant difference in numbers for both types of fibers between all three genotypes (P  0.4).
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Methods) to obtain a colony with a genetic background similar
to that of the -synuclein null mutant mice.
Numbers of nerve fibers in saphenous nerves of wild-type
and null mutant mice. To determine whether the absence of
synucleins affected growth and myelinization of axons of sen-
sory neurons, we examined the mouse saphenous nerve, which
contains mostly afferent sensory nerve fibers, and counted the
numbers of myelinated A-fibers and unmyelinated C-fibers. No
differences in the general ultrastructural morphology of the
fibers (not shown) or in their numbers (Fig. 6c and d) in
-synuclein and -synuclein null mutant mice compared to the
wild-type mice were found.
Survival in culture of peripheral nervous system neurons of
wild-type and null mutant mice. Although no differences in
neuron numbers in DRG or trigeminal ganglia of wild-type,
-synuclein, and -synuclein null mutant mice were found, it
was feasible to check whether neurons with an incorrect bal-
ance of synucleins are more sensitive to various stresses than
wild-type neurons. For this we compared the survival of neu-
rons from peripheral ganglia of null mutant and wild-type mice
in dissociated primary cultures. Dissociated cultures of P2 tri-
geminal ganglion neurons were prepared and neuronal survival
was assessed as described previously (42). Survival character-
istics of -synuclein- and -synuclein-deficient neurons were
FIG. 7. Survival of P2 mouse trigeminal ganglion neurons in dissociated primary culture. Cultures were prepared and treated with drugs as
described in Materials and Methods. Bar charts illustrate survival of neurons 48 h after initial count and addition of drugs. The number of surviving
neurons is expressed as a percentage of the initial count. Means and standard errors of data obtained from analysis of at least six culture dishes
for each genotype in two independent experiments are shown. (a) Both -synuclein-deficient (	/	) and -synuclein-deficient (	/	) neurons have
the same survival rate as wild-type (/) neurons in the presence of nerve growth factor (NGF) and are unable to survive in its absence (P  0.8,
Kruskal-Wallis one-way ANOVA). (b to d) Various treatments have the same effect on -synuclein deficient (	/	) neurons as they have on
wild-type (/) neurons (P  0.5 for all conditions; two-tailed, unpaired Student’s t test). Proteasome inhibitors (5 M MG-132 or 10 M
proteasome inhibitor I [PSI]) or heavy metal ions (30 M CuSO4 or 75 M ZnSO4) were added to neurons after the initial count at 24 h after
plating (b). In one set of experiments neurons were plated in neurobasal medium supplemented with B27 without antioxidants (c). In other cases,
DNA-damaging agents (10 M cytosine arabinoside [AraC] or 10 M Etoposide) or inhibitors of the JNK signaling pathway (20 M SP600125),
ERK signaling pathway (20 M PD98059), or phosphatidylinositol 3-kinase signaling pathway (20 M LY294002) were added to neurons after the
initial count at 3 h after plating (c and d).
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indistinguishable from those of wild-type neurons; they sur-
vived similarly well in the presence of nerve growth factor and
failed to survive in its absence (Fig. 7a). Similar results were
obtained for P2 superior cervical ganglion neurons (data not
shown). It has been shown previously that certain types of cells
with modified expression of synucleins, particularly dopami-
nergic neurons overexpressing -synuclein, have normal sur-
vival characteristics under optimal culture conditions but are
substantially more susceptible to stresses (37, 38, 41, 50, 51).
To determine whether the absence of -synuclein renders neu-
rons more sensitive to various toxic insults, we cultivated P2
trigeminal neurons in the absence of antioxidants or in the
presence of DNA-damaging agents (Fig. 7c), proteasome in-
hibitors, heavy metal ions (Fig. 7b), and inhibitors of major
intracellular signaling pathways (Fig. 7d) in the medium. None
of these treatments revealed differences in the survival of
-synuclein-deficient neurons compared to wild-type neurons.
Sensory reflexes and effects of CCI in wild-type and
-synuclein null mutant mice. The behavioral reflex responses
of adult male -synuclein null mutant and wild-type littermate
mice to noxious radiant heat and graded mechanical stimuli
were studied as described in Materials and Methods. In both
tests the behaviors of mice from these two groups were indis-
tinguishable (Fig. 8). To examine the effects of sciatic nerve
injury on behavioral reflex responses, we used the CCI model
of neuropathic pain. Over 7 to 10 days following CCI, wild-type
and mutant mice progressively developed marked ipsilateral
thermal hyperalgesia (reduced paw withdrawal latency) (Fig.
8a and b) and mechanical allodynia (reduced paw withdrawal
threshold) (Fig. 8c and d). All responses from the contralateral
hind limb remained unaltered. The time courses of recovery
from the consequences of CCI were very similar for mice of
both genotypes (Fig. 8). These results suggest that degenera-
tion and regeneration of the injured nerve and neuronal plas-
FIG. 8. Behavioral analysis of mice with CCI to the sciatic nerve. Data show mean (
 standard error of the mean) responses taken over a period
of up to 13 days before and every 2 to 6 days following surgery in wild-type mice (a and c) (n  9) and -synuclein null mutant mice (b and d) (n
 6). (a and b) Paw withdrawal latency (PWL) from a noxious thermal stimulus (Hargreaves’ thermal stimulator) ipsilateral to CCI (E) showed
significant differences between postoperative and preoperative values (†, P  0.05; Kruskal-Wallis one-way analysis of variance) and from
postoperative, contralateral () values (*, P  0.05 by Student’s t test) for both wild-type (a) and mutant (b) mice. No thermal hyperalgesia was
seen on the contralateral side. (c and d) Paw withdrawal thresholds (PWT) from mechanical stimulation (von Frey filaments) showed significant
differences between postoperative and preoperative values on the side ipsilateral (E) to CCI (†, P  0.05; Dunn’s method analysis of variance on
ranks) and between postoperative ipsilateral and contralateral () values (*, P  0.05, Mann-Whitney U-test) for both wild-type (c) and mutant
(d) mice.
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ticity in the spinal cord are not compromised in -synuclein null
mutant mice.
DISCUSSION
We have shown that in embryonic motoneurons -synuclein
is uniformly distributed through the cytoplasm of cell bodies
and axons. However, with the exception of a few neurons in the
facial nucleus, the cytoplasm of cell bodies of motoneurons of
the adult cranial somato- and branchiomotor nuclei is
-synuclein negative, whereas their axons and synaptic boutons
in neuromuscular junctions are intensively stained with anti--
synuclein antibody. Previously published in situ hybridization
data demonstrated high levels of -synuclein mRNA in cranial
motor nuclei of adult brain (7). Therefore, in motoneurons
during postnatal development, -synuclein undergoes a com-
partmentalization shift, which might reflect a functional shift.
Our results contradict recently published data (32) which dem-
onstrated the presence of -synuclein in cell bodies of mo-
toneurons in brain stem motor nuclei of adult rats. This might
reflect a difference between species; however, a more plausible
explanation is the difference in the antibodies used in the two
studies. In the present study, a highly specific antibody gener-
ated against mouse -synuclein C-terminal peptide was used,
whereas Li et al. (32) used an antibody generated against
human recombinant -synuclein whose specificity has been
checked with recombinant human synucleins but not with sam-
ples from null mutant animals.
It is not clear why some neurons of the adult facial nucleus
do not follow the common rule and continue to accumulate
-synuclein in the cytoplasm of their cell bodies. In this aspect
they resemble peripheral sensory neurons, in which no devel-
opmental changes of intracellular compartmentalization of
-synuclein take place and which have equally high levels of
-synuclein in their cell bodies and processes during embryo-
genesis and postnatally. We found that both neural crest-de-
rived DRG and placode-derived trigeminal sensory neurons
have this unchanging pattern of -synuclein intracellular com-
partmentalization. Taken together, our expression studies
demonstrated that between neurons expressing the highest lev-
els of -synuclein throughout development, two subpopula-
tions could be specified. The first includes peripheral sensory
neurons and some motoneurons of the facial nucleus, which
localize -synuclein in their cell bodies and axons at all devel-
opmental stages. Most other motoneurons of the brain stem
nuclei comprise the second group, which is characterized by
the developmental shift of -synuclein compartmentalization.
The high levels of expression suggest that -synuclein should
have an important role in the development and function of
sensory and motoneurons. Consequently, the loss of this pro-
tein could affect the morphology and/or physiology of animal
sensory and motor systems. To check this, we produced mutant
mice with complete inactivation of the -synuclein gene. Sim-
ilarly to previously reported -synuclein null mutants (1, 8, 46,
48), these mice showed no obvious phenotypical changes. De-
tailed studies of sensory and motoneurons in vivo and in vitro
failed to detect any difference between -synuclein null mutant
and wild-type mice. The number of neurons is not changed in
either of the subpopulations described above, suggesting that
proliferation, migration, differentiation, or programmed cell
death is not affected by the absence of -synuclein. Consis-
tently, survival of -synuclein-deficient neurons in primary cul-
ture is not different from survival of wild-type neurons. More-
over, the absence of -synuclein does not render these neurons
either more or less sensitive to any of the survival-affecting
factors studied so far. Because mid-brain dopaminergic neu-
rons seem to be most vulnerable to changes of synuclein me-
tabolism (references 10, 28, and 33 and references therein), it
is feasible that this neuronal population might be more sensi-
tive to changes in the synuclein ratio than motoneurons and
sensory neurons. We are currently testing whether the absence
of -synuclein affects survival of dopaminergic neurons in the
substantia nigra and ventral tegmental area of null mutant
mice.
It has been suggested previously that -synuclein could be
involved in axonal growth and stabilization of axon architec-
ture (6). However, we did not find differences in the morphol-
ogy and number of myelinated or unmyelinated fibers in the
saphenous nerves of mutant and wild-type mice. Sensory reflex
thresholds were also intact in -synuclein null mutant mice.
Nerve injury led to similar changes in sensory function in
wild-type and mutant mice. Normalization of sensory function
after nerve injury is believed to be associated with neuronal
plasticity in the spinal cord and axonal regeneration processes
in the injured peripheral nerve (9, 14, 21, 58). These processes
require remodeling of the axonal cytoskeleton, including the
neurofilament network, and involvement of -synuclein in reg-
ulation of neurofilament network integrity has been suggested
previously (6). However, the time course of sensory recovery
after CCI in -synuclein null mutant mice is the same as that in
wild-type mice, which suggested that nerve regeneration and
plasticity of early somatosensory pathways in -synuclein mu-
tant mice were unaffected.
The most straightforward explanation of our results is that
despite high levels of expression, -synuclein is not essential
for the development and function of motor and peripheral
sensory neurons. Nevertheless an alternative explanation is
also possible. This function(s) could be vital for vertebrate
organisms, and therefore effective mechanisms of protection
against its loss have been developed in evolution. The presence
of three closely related synucleins in all vertebrates and sub-
stantial overlapping of their expression patterns readily suggest
that they are able to compensate for each other’s function(s).
It is unlikely that compensation for the loss of one synuclein
function in mice is achieved by a simple increase of expression
of other synucleins. We found no difference in the levels of
mRNAs encoding the two remaining synucleins in several neu-
ronal populations of -synuclein null mutant mice, and the
same has been demonstrated before for -synuclein null mu-
tant mice (1). However, it is possible that it is not necessary to
boost an already high level of synuclein expression, because
changes in compartmentalization, posttranslational modifica-
tions, or interaction with other macromolecules could be re-
quired and sufficient for functional compensation. Detailed
studies of these processes in synuclein null mutant mice as well
as studies of double and triple synuclein mutants should shed
more light on this problem and finally reveal the normal func-
tions of these proteins.
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